Drug Trial Radar · NCT00025402
Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia
Last checked: Nov 19, 2026Latest source record: Dec 18, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,000
Planned (sponsor's estimate)
Start
Jul 1997
Primary completion
Not stated
Sponsor
- Lead sponsor
- III. Medizinische Klinik MannheimAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Giving chemotherapy, such as hydroxyurea, cytarabine, idarubicin, and etoposide before a donor bone marrow transplant or stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. Interferon alfa may interfere with the growth of cancer cells and slow the growth of cancer. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. It is not yet known whether chemotherapy is more effective with or without interferon alfa and/or bone marrow or stem cell transplant in treating patients with chronic myelogenous leukemia. PURPOSE: This randomized phase III trial is studying chemotherapy and biological therapy to see how well it works compared with chemotherapy, biological therapy, and donor bone marrow transplant or autologous stem cell transplant in treating patients with chronic phase chronic myelogenous leukemia.
Conditions
- Leukemia
Interventions
filgrastimBiological
recombinant interferon alfaBiological
busulfanDrug
cyclophosphamideDrug
cytarabineDrug
etoposideDrug
hydroxyureaDrug
idarubicinDrug
allogeneic bone marrow transplantationProcedure
peripheral blood stem cell transplantationProcedure
radiation therapyRadiation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Survival
- Frequency, time-point, and duration of hematologic and cytogenetic remissions and of Philadelphia chromosome-negative and/or BCL-ABL-positive cells
- Correlation of quality of hematological and cytogenetic remission with survival time
- Course of the terminal phase
- Toxicity
- Effect of prognostic criteria and normal or subnormal WBC on chronic phase duration and survival time
- Effect of early vs late high-dose therapy and autografting on feasibility, toxicity and survival times
Locations
188 sites in 5 countries. Site status is shown where the registry gives one.
Masaryk University Hospital
Brno, Czechia
Haematologisch Onkologische Praxis
Aachen, Germany
Kinderklinik - Universitaetsklinikum Aachen
Aachen, Germany
Urologische Klinik - Universitaetsklinikum Aachen
Aachen, Germany
Kreiskrankenhaus
Aalen, Germany
Klinikum St. Marien
Amberg, Germany
Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie
Ansbach, Germany
II. Medizinische Klinik
Aschaffenburg, Germany
Haematologische Praxis
Augsburg, Germany
Klinikum Augsburg
Augsburg, Germany
Kreiskrankenhaus
Bad Hersfeld, Germany
Krankenhaus Hohe Warte Mediziniche Klinik
Bayreuth, Germany
St. Hedwig Kranken Haus
Berlin, Germany
Tumorzentrum Berlin-Moabit
Berlin, Germany
Wenckebach - Krankenhaus
Berlin, Germany
Helios Klinikum Berlin
Berlin, Germany
Haematologisch-Onkologische Schwerpunktpraxis
Berlin, Germany
Charite - Campus Charite Mitte
Berlin, Germany
Onkolog - Haematolog Schwerpunktpraxis
Berlin, Germany
Krankenhaus Neukoelln
Berlin, Germany
Charite - Campus Virchow Klinikum
Berlin, Germany
Kinderklinik der Freier Universitaet Berlin
Berlin, Germany
Onkologische Schwerpunktpraxis Bielefeld
Bielefeld, Germany
Franziskus Hospital
Bietigheim, Germany
Krankenhaus Bietigheim
Bietigheim, Germany
Kreiskrankenhaus Boeblingen
Böblingen, Germany
Europahochhaus
Bochum, Germany
Universitaetsklinikum Bonn
Bonn, Germany
Medizinische Poliklinik
Bonn, Germany
Marienhospital Bottrop gGmbH
Bottrop, Germany
Staedtisches Klinikum Braunschweig
Braunschweig, Germany
Klinikum Bremen-Mitte
Bremen, Germany
St. Joseph Hospital
Bremerhaven, Germany
Zentralkrankenhaus
Bremerhaven, Germany
Medizinische Klinik Am Lukas - Krankenhaus
Bünde, Germany
Klinikum Coburg
Coburg, Germany
Praxis Gemeinschaft
Cologne, Germany
Praxis Fuer Haematologie Internistische Onkologie
Cologne, Germany
Medizinische Universitaetsklinik I at the University of Cologne
Cologne, Germany
Onkologische Schwerpunktpraxis
Cottbus, Germany
Showing 40 of 188 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.